Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy
This study is currently recruiting participants.
Study NCT00460070   Information provided by Rikshospitalet University Hospital
First Received: April 12, 2007   Last Updated: October 2, 2009   History of Changes

April 12, 2007
October 2, 2009
January 2007
 
 
 
Complete list of historical versions of study NCT00460070 on ClinicalTrials.gov Archive Site
 
 
 
Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy
Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.

Some antiepileptic drugs are found to have hormonal side effects. We want to study possible hormonal side effects of the relatively new antiepileptic drug; levetiracetam and compare it to the older drugs; lamotrigine and carbamazepine. The participants are going to fill in a questionnaire and we will collect blood samples from them, to analyse hormones.

We have previously performed long-term studies of rats treated with levetiracetam and compared them with a control group. Here we have found that levetiracetam has a probable effect on the ovaries, since the treated animals had larger ovaries, fewer cysts, more corpora lutea and more secondary follicles than the untreated animals (Taubøll et al 2004). Blood tests on the animals showed that those treated with levetiracetam had higher testosterone levels and lower levels of estrogen and FSH, whilst LH and progesterone levels were unaffected by the treatment (Svalheim et al, 2005a, b). Studies on cell cultures from pig ovaries, as carried out by our group in collaboration with Jagiellonian University, Krakow, Poland, appeared to support these findings (Taubøll et al. 2006, submitted).

Our wish therefore now is to study fertile men and women in order to look for any changes in the balance of sex hormones during use of levetiracetam in order to establish whether the findings in animal trials are clinically relevant to humans.

 
Observational
Cohort, Cross-Sectional
Epilepsy
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
240
December 2007
 

Inclusion Criteria:

  • Having epilepsy
  • Age 18- 45
  • Using levetiracetam/ lamotrigine or carbamazepine in monotherapy for at least 6 months

Exclusion Criteria:

  • Hormonal diseases( ie; diabetes, hypo/ hyperthyroid disease)
  • Use of hormonal anticonception drugs or other hormonal drugs.
Both
18 Years to 45 Years
Yes
Contact: Erik Taubøll, MD +4723070000 erik.tauboll@rikshospitalet.no
Contact: Sigrid Svalheim, MD ?4723070000 sigrid.svalheim@rikshospitalet.no
Norway
 
NCT00460070
Erik Taubøll, Professor, Dep of Neurology, Rikshospitalet, OSLO
M52332
Rikshospitalet University Hospital
GlaxoSmithKline
Principal Investigator: Erik Taubøll, MD unaffiliation
Rikshospitalet University Hospital
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP